Cynomolgus monkey (relevant); rat non-binding (exploratory, MMAE-related effects)
“In addition, these studies support the use of cynomolgus monkey as the pharmacologically relevant species for toxicity assessments of telisotuzumab vedotin.”
✓ VerifiedFDA multi-discipline review, p. 33Source ↗
Why that species
Binds human and monkey c-Met with similar EC50 (1.3 vs 1.5 nM); no binding to mouse, rat, rabbit c-Met
“In vitro, telisotuzumab bound to cells overexpressing human or monkey c-Met with EC50 values of 1.3 and 1.5 nM, respectively, but did not bind to cells expressing mouse, rat, or rabbit c-Met.”
✓ VerifiedFDA multi-discipline review, p. 33Source ↗
Surrogate molecule
No surrogate; clinical ADC in monkey; MMAE payload data via Seagen right of reference
“The Applicant used information on the pharmacology, pharmacokinetics (PK), and toxicology profile of MMAE provided via right of reference from Seagen.”
✓ VerifiedFDA multi-discipline review, p. 33Source ↗